.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Zydus Lifesciences recently launched the PEPAIR OPEP device to support patients with chronic lung conditions. This handheld tool assists individuals suffering from COPD, asthma, and bronchiectasis. Furthermore, it represents India's first affordable solution for airway clearance at just Rs. 990. Because chronic mucous hypersecretion affects over 90 lakh Indian patients, this launch is a significant healthcare milestone. Consequently, Zydus aims to simplify pulmonary rehabilitation across the country.
The device utilizes Oscillating Positive Expiratory Pressure therapy to clear airway congestion. When patients exhale through the translucent device, it generates specific pressure and vibrations. These oscillations effectively loosen stubborn mucous from the bronchial walls. Additionally, the patented three-resistance system allows for customized therapy based on patient needs. Therefore, users can achieve better breathing without the need for additional medication.
Respiratory diseases are rising sharply in India due to extreme air pollution and rapid urbanization. Specifically, delayed diagnosis of chronic lung conditions often leads to impaired mucociliary pathways. However, the PEPAIR OPEP device helps remove airway obstructions and reduces persistent coughing. Zydus developed this innovation in agreement with AeroDel Technology Innovations. Moreover, clinical guidance recommends OPEP therapy for effective everyday care.
Q1: What is the primary function of the PEPAIR OPEP device?
The PEPAIR OPEP device creates pressure and vibrations during exhalation to loosen mucous and open airways. It functions as a drug-free tool to assist patients with COPD, asthma, and bronchiectasis in clearing their lungs.
Q2: Who can benefit from using this device?
It is specifically designed for individuals with chronic respiratory conditions who suffer from excessive mucous production. This includes patients with asthma or bronchiectasis seeking an affordable airway clearance solution.
Q3: How much does the PEPAIR device cost in India?
Zydus has launched the device at an affordable price of Rs. 990 per unit to ensure broader accessibility for Indian patients.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or replace professional judgment. Refer to the latest local and national guidelines for clinical practice.
References
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
Zydus Lifesciences launches PEPAIR, an affordable OPEP device to assist Indian patients with COPD, asthma, and bronchiectasis in clearing airway mucous....
5 months ago
Andhra Pradesh reported 10 new Covid-19 cases, taking the state tally to 49 while deaths remain at four. With 24 patients hospitalized and 16 under home isolation, the Health Department has intensified monitoring. Medical professionals should review regional distribution, diagnostic protocols, and management plans.
Today
An 11-year Swedish registry study of 618 uterine sarcoma patients found that minimally invasive surgery yielded survival comparable to open surgery in early stages. However, adjuvant chemotherapy conferred no survival benefit in localized or advanced disease, highlighting stage and histology as key outcomes.
3 days back
A cross-sectional study evaluates post-intensive care syndrome in cardiac patients 2-4 weeks post-ICU discharge, highlighting cognitive, psychological, and functional impairments and the need for structured multidisciplinary rehabilitation.
3 days back
Anterior cruciate ligament reconstruction failure lacks uniform definition. A narrative review proposes an integrative framework incorporating objective and subjective instability, persistent pain, restricted motion, graft rupture, and secondary meniscal injury to standardize clinical reporting.
3 days back
With World Obesity Atlas data warning that over 41 million Indian children are overweight or obese, ICMR and NIN have unveiled a 10-point policy roadmap. The initiative calls for mandatory front-of-pack labeling, HFSS taxes, strict marketing bans, and healthier school environments to curb non-communicable diseases.
Today
